Unigen’s superior regulatory and science teams are adding value to Canadian market joint care brands with the announcement of Health Canada’s approval of 3 day and 5 day fast acting health claims for Univestin®, Unigen’s premier joint health ingredient.
Unigen is partnering with China’s top tier Institute of Chinese Materia Medica to complete DNA barcoding of botanicals and marines in Unigen’s proprietary PhyoLogix™ collection.
Unigen, Inc. has published a study showing Univestin has no adverse effects on the Cardiovascular, Respiratory and Central Nervous Systems.
Unigen, Inc. publishes extensive 26-week toxicity study; providing further validation for Univestin’s long-term safety.
Unigen, Inc. continues to fulfill their mission to bring the best of nature to humankind with new ingredients offerings and more research.
Univestin® proprietary joint health ingredient debuts with new branding, logo, marketing materials all designed to promote the Univestin Triple Play: Accelerated Action, Lasting Comfort, Long-term Safety.
Unigen continues to add to the extensive body of research surrounding Univestin®, their innovative joint health ingredient, with new studies on the effects of the compound on reproduction in rats. Unigen performed 3 separate but related studies, labeled as Part-I through III. Each part addresses a different aspect of fertility, reproduction and development.
Unigen, Inc. announced today that Grant Bergstrom joined the company to help further expand the awareness and distribution of the firm’s scientifically proven ingredients.
Unigen, Inc. announced today that Rodney Storms joined the company as Regional Sales Director.
Unigen, Inc. announced today that Regan Miles has been selected to lead the company as President and CEO.
Marketing Manager, Unigen